Epigenetics in multiple myeloma: From mechanisms to therapy

Area of Science:

• Hematology
• Oncology
• Epigenetics

Background:

• Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow.
• Genetic mutations and tumor microenvironment interactions are known MM drivers.
• Epigenetic deregulation is increasingly recognized as a key factor in MM pathogenesis.

Purpose of the Study:

• To review the current understanding of epigenetic mechanisms in multiple myeloma.
• To highlight the role of epigenetics in MM initiation, progression, and treatment response.
• To explore the therapeutic potential of epigenetic inhibitors for MM.

Main Methods:

• Review of recent studies and data from MM sequencing and expression projects.
• Analysis of epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNAs.
• Synthesis of knowledge on the interplay between epigenetics and MM.

Main Results:

• Epigenetic modifiers are frequently deregulated in MM.
• Epigenetic mechanisms significantly impact MM initiation, progression, and heterogeneity.
• Epigenetic alterations influence patient response to therapies.

Conclusions:

• Epigenetics plays a critical role in multiple myeloma pathogenesis.
• Epigenetic inhibitors represent a promising avenue for future MM treatment modalities.
• Further research into epigenetic mechanisms is vital for advancing MM therapy.